Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

Authors: Paul F. Schellhammer, Gerald W. Chodak, James B. Whitmore, Robert B. Sims, Mark W. Frohlich, Philip W. Kantoff - Urology 2013 cited by 242